Results of the valve-preserving operations in the patients, suffering aortal dissection Type A

Objective. To investigate resuspension of aortal valve in the patients, suffering aortal dissection of Type A. Materials and methods. In 1994 - 2018 yrs period in Amosov National Institute of Cardio-Vascular Surgery 385 patients, suffering an acute aortal dissection Type A, were treated. In 169 patients aortal dissection have led to occurrence of an acute aortal insufficiency. Among these patients resuspension of the aortal valve was performed in 43, who have got aortal insufficiency from moderate one to severe. Results. In 43 patients with initial aortal insufficiency, from moderate one to severe, to whom resuspension of aortal valve was performed, postoperatively, in accordance to data of echocardiography, its function have appeared competent. During the year after primary intervention in 2 patients the aortal valve prosthesis was performed for severe aortal insufficiency developed. Conclusion. Resuspension of aortal valve constitutes an effective method of its function restoration in patients, suffering aortal dissection Type A and aortal insufficiency from moderate to severe. Preservation of own aortal valve improves patient’s quality of life, lowers the risks of thromboembolic and hemorrhagic complications and prevents delay for thrombing of a false channel due to long-lasting anticoagulant therapy.

Download Full-text

Quality of life after acute aortic dissection type A: Younger patients are stronger impaired in the longterm course

The Thoracic and Cardiovascular Surgeon ◽

10.1055/s-0032-1332430 ◽

2013 ◽

Vol 61 (S 01) ◽

Author(s):

M Endlich ◽

M Hamiko ◽

C Probst ◽

F Mellert ◽

A Welz ◽

...

Keyword(s):

Quality Of Life ◽

Aortic Dissection ◽

Acute Aortic Dissection ◽

Type A ◽

Younger Patients ◽

Aortic Dissection Type A

Download Full-text

Forty-three year survival with the ball-in-cage heart valve prosthesis (MKCH model 02) in the mitral position of a female patient: hemodynamic result, health-related quality of life, medication therapy correction

Kreativnaya kardiologiya ◽

10.24022/1997-3187-2019-13-3-274-284 ◽

2019 ◽

Vol 13 (3) ◽

pp. 274-284

Author(s):

T.G. Nikitina ◽

D.M. Pelekh ◽

A.A. Fadeev ◽

L.A. Glushko ◽

V.E. Il'yina ◽

...

Keyword(s):

Quality Of Life ◽

Female Patient ◽

Heart Valve ◽

Valve Prosthesis ◽

Health Related Quality ◽

Medication Therapy ◽

Mitral Position ◽

Related Quality ◽

Health Related

Download Full-text

Cardiovascular Disorders in Autoimmune Disease

Clinical Cardiology and Cardiovascular Interventions ◽

10.31579/2641-0419/015 ◽

2019 ◽

Vol 2 (2) ◽

pp. 01-04

Author(s):

Delcio G Silva Junior

Keyword(s):

Quality Of Life ◽

Risk Factors ◽

Cardiovascular Events ◽

Cvd Risk Factors ◽

Cvd Risk ◽

Cardiovascular Patients ◽

Cardio Vascular Disease ◽

Traditional Risk Factors ◽

Cardio Vascular

The presence of Cardio Vascular Disease (CVD) impacts negatively on expectation and quality of life of the population, being one of the main causes of disability. Many of those who become cardiovascular patients throughout their life could have had different evolution if preventive attitudes were taken. Since 50’s decade, Framingham studies have shown the importance of predetermining factors for CVD occurrence. The classical CVD risk factors such as diabetes, metabolic syndrome, dyslipidemia, hypertension, smoking and family history are well established as predictors of cardiovascular events. The presence of Cardio Vascular Disease (CVD) impacts negatively on expectation and quality of life of the population, being one of the main causes of disability. Many of those who become cardiovascular patients throughout their life could have had different evolution if preventive attitudes were taken. Since 50’s decade, Framingham studies have shown the importance of predetermining factors for CVD occurrence. The classical CVD risk factors such as diabetes, metabolic syndrome, dyslipidemia, hypertension, smoking and family history are well established as predictors of cardiovascular events. However, in certain clinical conditions, traditional risk factors seem not to fully explain the incidence of CVD. Coronary artery disease and early atherosclerosis in young women with Systemic Lupus Erythematosus (SLE) are one of the best examples of how chronic inflammatory diseases can affect individuals who are normally poorly exposed to traditional risk factors. Even with the plurality of extra-articular manifestations of rheumatologic diseases, such as pulmonary hypertension and SLE encephalopathy, uveitis in spondyloarthritis, or as Achalasia in scleroderma, attention is being paid to the frequent cardiovascular system involvement in these patients, especially in the vascular territory

Download Full-text

A Double-Blind, Randomized, Placebo-Controlled Health-Outcomes Survey of the Effect of Botulinum Toxin Type A Injections on Quality of Life and Self-Esteem

Dermatologic Surgery ◽

10.1111/j.1524-4725.2010.01795.x ◽

2010 ◽

Vol 36 ◽

pp. 2088-2097 ◽

Cited By ~ 48

Author(s):

STEVEN H. DAYAN ◽

JOHN P. ARKINS ◽

AMIT B. PATEL ◽

THOMAS J. GAL

Keyword(s):

Quality Of Life ◽

Botulinum Toxin ◽

Health Outcomes ◽

Botulinum Toxin Type A ◽

Type A ◽

Botulinum Toxin Type ◽

Self Esteem ◽

Double Blind

Download Full-text

Patient perspectives on the therapeutic profile of botulinum neurotoxin type A in cervical dystonia

Journal of Neurology ◽

10.1007/s00415-020-10217-7 ◽

2020 ◽

Author(s):

Cynthia Comella ◽

Joaquim J. Ferreira ◽

Emilie Pain ◽

Marion Azoulai ◽

Savary Om

Keyword(s):

Quality Of Life ◽

Cervical Dystonia ◽

Botulinum Neurotoxin ◽

Type A ◽

Peak Effect ◽

Botulinum Neurotoxin Type A ◽

The Mean ◽

The Impact ◽

Therapeutic Profile

Abstract Background Botulinum neurotoxin type A (BoNT-A) is an effective pharmacological treatment for the management of cervical dystonia (CD) that requires repeated administration at variable intervals. We explored patient perceptions of the impact of CD and the waning of BoNT-A therapeutic effects. Methods An internet-based survey was conducted through Carenity, a global online patient community, from May to September 2019. Eligible respondents were adults with CD who had ≥ 2 previous BoNT-A injections. Results 209 respondents (81% females; mean age of 49.7 years) met the screening criteria. The mean BoNT-A injection frequency was 3.9 injections/year. The mean reported onset of BoNT-A therapeutic effect was 11.7 days and the time to peak effect was 4.5 weeks. Symptom re-emergence between injections was common (88%); the time from injection to symptom re-emergence was 73.6 days (~ 10.5 weeks). Treatment was not reported to completely abolish symptoms, even at peak effect. However, symptom severity was rated (0 = no symptoms; 10 = very strong symptoms) as lowest at the peak of treatment effects (mean scores ~ 3/10), increasing as the effects of treatment start waning (~ 5.5/10) and was strongest one day before the next session (~ 7–8/10). The impact of CD on quality of life followed the same ‘rollercoaster’ pattern. Conclusions This survey highlights the burden of CD symptoms, even in patients undergoing regular treatment. Symptom re-emergence is common and has significant impact on daily activities and quality of life. Greater awareness of the therapeutic profile of BoNT-A treatment should lead to better informed therapeutic discussions and planning.

Download Full-text